Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Gold/Mining/Energy : Inflazyme Pharmaceuticals (T.IZP) -- Ignore unavailable to you. Want to Upgrade?

To: Chuca Marsh who wrote (1294)	9/2/1999 6:40:00 PM
From: Luc Richard	Read Replies (1) \| Respond to of 1501

It's seem a low % but if we take a good look at Sean reference of FDA, only one on five will go commercial at the beginning of phase 1. Only two on ten will go commercial and possibly have success. But we have a good prospect here. First, we know that there is no big side effects on animals. Second, there is no steroid effects and the steroids have these effects on animals. Usually, the same logic will be respected with phase 1 clinical trials. There will be no steroid side effects on humans. Third, the sheep model is very good for asthma and we see a lowering of about 90 % of asthmatic reaction ( of the two phase-- immediate and late ). That is very good and will eventually be the same for humans. So we are now at the beginning of phase 3, the most important. If we can have a medication by mouth that has the efficiency of steroids, with few side effects, we have a BMW here. And I don't take in consideration the other medication who is in development for arthritis, psoriasis and inflammatory bowel syndrome. So I I'm very confident but knowing the risk... Luc Richard